LongevityEvidence: Limited5 min read

Epitalon: Strong Claims, Thin Evidence — What the Studies Actually Say

Epitalon carries some of the boldest marketing in the longevity category and one of the weakest evidence grades in our library. Both facts deserve equal billing.

10mg

Typical vial

$27

Lowest tracked

$45

Median price

108

Vendors listing

The research base

Around 33 studies reference the tetrapeptide, largely originating from a single research lineage, frequently single-group, and often without blinding or independent replication.

That combination is why we grade the evidence as Limited rather than Emerging. Interesting is not the same as demonstrated.

Telomerase claims

The commonly cited telomerase findings come from small in-vitro and animal experiments. Extrapolating those to human lifespan outcomes is not supported by the published record.

Any vendor page presenting lifespan extension as established fact is overstating the literature.

Pricing

10mg vials generally run £21 to £36 across tracked suppliers, with a narrower spread than most categories.

Documentation

Because the compound is short and easy to synthesise, purity results are usually good. Batch matching and lab identification remain the useful signals.

Frequently asked

Why is the evidence graded Limited?

Few studies, narrow provenance, small samples, and little independent replication.

Search focus for this profile

epitalon6,600/mo searches, difficulty 49/100 — possible. Source: Semrush (UK database).

Supporting terms covered: epitalon review, epithalon telomerase study, longevity peptide research.

Everything below describes published research and market data. Nothing here is medical advice, and none of these compounds are sold or supplied by CheckALab.

More in Longevity